Study outcomes were analyzed with a repeated-measures model using the Statistical Analysis System (SAS), version 9.2 (SAS Institute Inc., 2007). Because of the small number of smokers (n=22) with Met/Met genotype, we combined Met/Met group with Met/Val and compared this combined group with the Val/Val group, similar to previous studies on COMT and cigarette smoking (16, 49). For blood pressure, heart rate and the DEQ, multiple assessments were collected for each saline and nicotine dose. For these outcomes, the model included the COMT rs4680 genotype (Val/Val vs. Val/Met or Met/Met), nicotine dose (saline, 0.5 and 1mg/70 kg), sex (male vs. female), race (African-American vs. Caucasian), nicotine metabolite ratio, BMI, and interaction terms including genotype × dose, genotype × race, and genotype × sex. In previous studies, race, sex, BMI, and NMR have been shown to modulate nicotine’s pharmacological effects (23, 50). For the NWSC, BQSU, PANAS, and cognitive measures, the assessments were completed at the beginning and end of the session. For these outcomes, the model included time of measurement (pre- vs. post-session), rather than the dose. Significant main effects
